



**INVEST LIKE A PRO, WITH THE PROS!**

---





Keep reading for news on *Cognativity Neurosciences (CSE:CGN)*.

---

[www.capitalideasmedia.com](http://www.capitalideasmedia.com)

---

**Morning Need to Know**

Getting you ready for your investing day

January 31, 2019

Written & compiled by Mark Bunting, Publisher,  
Capital Ideas Media

---



---

## CANADIAN ANALYSTS' CALLS

---

### INITIATIONS

**Argonaut Gold (TSX:AR)**. National Bank starts coverage with a "buy" and a price target of \$3.50 (Canadian).

\*\*

**Labrador Iron Ore Royalty (TSX:LIF)**. Eight Capital upgrades to "buy" and moves the target to \$40 from \$32.

**WSP Global (TSX:WSP)**.

Desjardins Securities upgrades to "buy" and keeps the target at \$76 after the company unveiled a three-year strategic plan.

CIBC ups the price target on WSP to \$77 from \$75 and maintains "outperformer" rating.

**CGI Group (TSX:GIB.A)** gets its target lifted to

\$95 from \$90 by Cannaccord Genuity after the company's strong Q1 results and positive outlook.

---



## U.S. ANALYSTS' CALLS

---

**Facebook (NASDAQ:FB)** RBC Capital Markets boosts the target to \$200 (U.S.) from \$190 and maintains "outperform", saying "*2.7 billion users can't be wrong*".

Canaccord Genuity hikes the target to \$200 from \$180 and keeps a "buy" rating on stable user trends and strong advertising growth. See below for more on FB's earnings.

**Pfizer (NYSE:PFE)**. Credit Suisse upgrades to "outperform" and lifts the target to \$47 from \$45. Argus Research upgrades to "buy" and keeps a \$55 target.

**Boeing (NYSE:BA)** Cowen & Co. lifts the target to \$745 from \$445 on the company's upbeat 2019 cash flow forecast.

**Anthem (NYSE:ANTM)**. JP Morgan raises the target to \$338 from \$293 citing the company's Q4 revenue and 2019 forecast.

---

## STOCKS THAT MAY MOVE

---

## **Cognetivity Neurosciences (CSE:CGN).**

The Globe and Mail today [has an article](#) saying the company's computerized cognitive test may be more effective than traditional pen-and-paper tests in diagnosing early cognitive impairment.

The study is co-authored by the company's CEO Sina Habibi and has been published in the journal Nature.

The test measures the speed and accuracy of a patient's ability to pick out animals in photographs on an iPad.

Cognetivity is U.K.-based with offices in Vancouver. The company is planning a clinical validation study and then will seek Health Canada approval for the technology in 2020.

We featured Cognetivity in the November 6, 2018 Digest based on a recommendation from contributor Fabrice Taylor when the stock was trading at \$0.56 (Canadian) a share. It closed Wednesday at \$0.40. We'll see how it does today.

**Tetra Bio-Pharma (TSXV:TBP)** is buying Panag Pharma for \$12 million in cash and stock.

**Exco Technologies (TSX:XTC)** is raising its

quarterly dividend by 6% to nine cents a share.

**Facebook (NASDAQ:FB)** is higher by 11% in pre-market trade after managing to beat analysts estimates with record profit, and as it grew its quarterly revenue year-over-year by 30%, the slowest in six years, despite a series of scandals.

**General Electric (NYSE:GE)** is higher by 10% after the conglomerate swung to a quarterly profit from continuing operations of \$666 million versus an \$11.2 billion loss last year. Ex-items earnings beat estimates but revenue, which rose 5%, missed forecasts.

**Tesla (NASDAQ:TSLA)** missed estimates with its earnings and its CFO is stepping down. He'll be replaced by the VP of Finance. The electric vehicle maker promises to be profitable in every quarter of 2019.

**Intel (NASDAQ:INTC)** has taken the interim tag off Robert Swan and named him CEO.

**Deutsche Bank (NYSE:DB)** expects a government brokered merger with German peer Commerzbank by the middle of this year if its prospects don't improve, according to Bloomberg News.

---

**MARKETS**

---

The TSX and U.S. equity futures are pointing higher and U.S. stocks are set for their strongest January in 30 years after U.S. Federal reserve chairman Jerome Powell singled the central bank was likely done raising interest rates for now.

Global stocks as measured by the MSCI all-country index are up about 7% in January and on pace for their largest monthly gain since the index was launched in 1988.

Canada's GDP dropped 0.1% in November in line with estimates.

German retail sales posted their largest monthly decline in more than a decade.

---

## CURRENCIES

---

The Canadian dollar is flat at \$0.7603 (U.S).

---

## COMMODITIES

---

West Texas Intermediate is up by 0.6% to \$54.56 a barrel, on pace for its largest January gain on record.

Gold is up 1% \$1,329.40 an ounce as the U.S. dollar slumps following the Fed's comments on interest rates.

---

## Daily Update

---

- ▶ Market Cap: \$484 million
- ▶ Three-Year return: 212%
- ▶ Projected Return: 25%

A reminder to check out the new [\*Capital Ideas Digest\*](#) for an under the radar company with a very strong 10-year track record of revenue and earnings growth that continues to reward shareholders.

---

Please email questions, comments or concerns to:

[\*customercare@capitalideasresearch.com\*](mailto:customercare@capitalideasresearch.com)

---

Access, ideas and insight.

[\*\*Mark Bunting\*\*](#)  
Publisher,  
[\*\*Capital Ideas Media\*\*](#)

[www.capitalideasmedia.com](http://www.capitalideasmedia.com)





---

The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or

implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

*Copyright © 2016 Capital Ideas Research, All rights reserved.*

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

---

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada